Platinum versus non-platinum chemotherapy regimens for small cell lung cancer-Reference-Cited by-同舟云学术

Platinum versus non-platinum chemotherapy regimens for small cell lung cancer

Published:2015-08-02 Issue:8 Volume:2015 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Amarasena Isuru U¹,Chatterjee Saion²,Walters Julia AE³,Wood-Baker Richard¹,Fong Kwun M⁴

Affiliation:

1. University of Tasmania; School of Medicine; 43 Collins Street Hobart Tasmania Australia 7005

2. Monash University and the Alfred Hospital; Victoria Australia 3800

3. School of Medicine, University of Tasmania; NHMRC Centre of Research Excellence for Chronic Respiratory Disease; MS1, 17 Liverpool Street PO Box 23 Hobart Tasmania Australia 7001

4. The Prince Charles Hospital; Department of Thoracic Medicine; Rode Road Brisbane Queensland Australia 4032

Publisher

Wiley

Subject

Pharmacology (medical)

Reference72 articles.

1. Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer;Baka;British Journal of Cancer,2008

2. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B;Chahinian;Journal of Clinical Oncology,1989 Aug

3. Phase II study of cisplatin, maytansine, and chlorozotocin in small cell lung carcinoma (EST 2578);Creech;Cancer Treatment Reports,1982 Jun

4. Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer;Jong;European Journal of Cancer,2007

5. An evaluation of low-dose cisplatin as part of combined modality therapy of limited small cell lung cancer;Eagan;Cancer Clinical Trials,1981

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world predictors of survival in patients with limited-stage small-cell lung cancer in Manitoba, Canada;Frontiers in Oncology;2023-12-06

2. Survival benefit with checkpoint inhibitors versus chemotherapy is modified by brain metastases in patients with recurrent small cell lung cancer;Frontiers in Oncology;2023-09-22

3. Assessing treatment outcomes of chemoimmunotherapy in extensive-stage small cell lung cancer: an integrated clinical and radiomics approach;Journal for ImmunoTherapy of Cancer;2023-09

4. Efficacy and safety of durvalumab + chemotherapy vs. atezolizumab + chemotherapy in the treatment of small-cell lung cancer: a retrospective comparative cohort study;Journal of Thoracic Disease;2023-06

5. Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial;Frontiers in Immunology;2023-04-11